FindTrial
Sign In

A prospective RCT study of insulin combined with low-molecular-weight heparin versus DFPP in the treatment of hypertriglyceridemic acute pancreatitis with very high triglyceride levels

A prospective randomized controlled study of insulin combined with low-molecular-weight heparin versus DFPP in the treatment of hypertriglyceridemic acute pancreatitis with very high triglyceride levels

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116055
Enrollment
Unknown
Registered
2026-01-05
Start date
2026-01-06
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertriglyceridemia (HTG)

Interventions

IHT group:Insulin plus low-molecular-weight heparin therapy
DFPP group:double-filtration plasmapheresis

Sponsors

Shanghai Jiading Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meets the 2024 ASG guideline criteria for HTG-AP; 2. Onset-to-admission interval =48 h; 3. Age 18–80 years; 4. Willing to provide written informed consent for study participation. Baseline TG >22.6 mmol/L measured on the day of admission.

Exclusion criteria

Exclusion criteria: 1.Pregnancy, malignancy, end-stage renal disease, coagulation disorders, prior plasmapheresis or long-term lipid-lowering therapy before admission, or any condition rendering DFPP unfeasible or intolerable.

Design outcomes

Primary

MeasureTime frame
serum triglycerides;—

Secondary

MeasureTime frame
IL-6, D-dimer, serum calcium, blood glucose, BUN, lactate, WBC, CRP, PCT, TNF-a; SIRS parameters; organ failure-related indices.;—

Countries

China

Contacts

Public ContactPengcheng Chen

Shanghai Jiading Central Hospital

cpc0315@126.com+86 21 67073247

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026